Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
13.27B
Market cap13.27B
Price-Earnings ratio
28.32
Price-Earnings ratio28.32
Dividend yield
Dividend yield
Average volume
1.23M
Average volume1.23M
High today
$132.77
High today$132.77
Low today
$129.09
Low today$129.09
Open price
$129.12
Open price$129.12
Volume
1.26M
Volume1.26M
52 Week high
$160.18
52 Week high$160.18
52 Week low
$84.23
52 Week low$84.23

Stock Snapshot

The current Neurocrine(NBIX) stock price is $132.25, with a market capitalization of 13.27B. The stock trades at a price-to-earnings (P/E) ratio of 28.32.

On 2026-03-01, Neurocrine(NBIX) stock traded between a low of $129.09 and a high of $132.77. Shares are currently priced at $132.25, which is +2.4% above the low and -0.4% below the high.

The Neurocrine(NBIX)'s current trading volume is 1.26M, compared to an average daily volume of 1.23M.

During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.

During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.

NBIX News

Simply Wall St 4d
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences?

In February 2026, Neurocrine Biosciences reported that fourth-quarter 2025 revenue rose to US$805.5 million and net income to US$153.7 million, with full-year r...

Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences?
Simply Wall St 5d
A Look At Neurocrine Biosciences Valuation After Positive Analyst Views And 2026 Guidance

Neurocrine Biosciences (NBIX) is back in focus after reporting fourth quarter and full year 2025 earnings, alongside fresh 2026 sales guidance for INGREZZA and...

A Look At Neurocrine Biosciences Valuation After Positive Analyst Views And 2026 Guidance
TipRanks 5d
Neurocrine initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Neurocrine (NBIX) with an Outperform rating and $160 price target The firm launched coverage of the neuroscience biotech se...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
16.1%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.